YMTX vs. CMRX, SCYX, PMVP, MIST, ONCY, MRNS, AFMD, EGRX, GNLX, and SPRO
Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Chimerix (CMRX), SCYNEXIS (SCYX), PMV Pharmaceuticals (PMVP), Milestone Pharmaceuticals (MIST), Oncolytics Biotech (ONCY), Marinus Pharmaceuticals (MRNS), Affimed (AFMD), Eagle Pharmaceuticals (EGRX), Genelux (GNLX), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry.
Yumanity Therapeutics (NASDAQ:YMTX) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Yumanity Therapeutics has a net margin of -660.61% compared to Chimerix's net margin of -25,337.96%. Chimerix's return on equity of -41.32% beat Yumanity Therapeutics' return on equity.
Chimerix has a consensus target price of $8.50, suggesting a potential upside of 855.06%. Given Chimerix's higher possible upside, analysts clearly believe Chimerix is more favorable than Yumanity Therapeutics.
In the previous week, Chimerix had 1 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 2 mentions for Chimerix and 1 mentions for Yumanity Therapeutics. Chimerix's average media sentiment score of 1.10 beat Yumanity Therapeutics' score of 0.00 indicating that Chimerix is being referred to more favorably in the news media.
Yumanity Therapeutics has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.
Chimerix received 372 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 63.59% of users gave Chimerix an outperform vote.
Yumanity Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
25.1% of Yumanity Therapeutics shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 12.5% of Yumanity Therapeutics shares are held by company insiders. Comparatively, 13.1% of Chimerix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Chimerix beats Yumanity Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Yumanity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Yumanity Therapeutics Competitors List
Related Companies and Tools
